Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study

A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy

(2013) Roberto Giugliani et al.   GENETICS IN MEDICINE

The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life

(2013) Mireia Raluy-Callado et al.   Orphanet Journal of Rare Diseases

Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up

(2011) A Tylki- Szymanska et al.   ACTA PAEDIATRICA

The role of enzyme replacement therapy in severe Hunter syndrome—an expert panel consensus

(2011) Joseph Muenzer et al.   EUROPEAN JOURNAL OF PEDIATRICS

Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey

(2011) Joseph Muenzer et al.   GENETICS IN MEDICINE

Hearing loss in patients with mucopolysaccharidosis II: Data from HOS – the Hunter Outcome Survey

(2011) Annerose Keilmann et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease

(2011) Maurizio Scarpa et al.   Orphanet Journal of Rare Diseases

First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: Case observations from the Hunter Outcome Survey (HOS)

(2010) C. Alcalde-Martín et al.   European Journal of Medical Genetics

Multidisciplinary Management of Hunter Syndrome

(2009) J. Muenzer et al.   PEDIATRICS

Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)

(2008) R. Martin et al.   PEDIATRICS